30/09/2025 – The Company will publish its financial report for the first half of 2025 on Friday 10 October, 2025, at the latest Download PDF Post navigationPreviousPrevious post:AB Science announces the successful completion of a 2.55 million euros private placementNextNext post:Revenues for the first half of 2025 and update on AB Science’s activitiesRelated PostsAB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040December 22, 2025AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per shareDecember 18, 2025AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancersDecember 15, 2025AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of functionDecember 11, 2025AB Science announces the successful completion of a 2.8 million euros private placementOctober 17, 2025Summary of the virtual conference held on October 16, 2025October 16, 2025
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040December 22, 2025
AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per shareDecember 18, 2025
AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancersDecember 15, 2025
AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of functionDecember 11, 2025
AB Science announces the successful completion of a 2.8 million euros private placementOctober 17, 2025
